FUNCTION ANALYSIS OF EUKARYOTIC PROTEIN KINASES AND PHOSPHO-REGULATORY SYSTEMS

真核蛋白激酶和磷酸调节系统的功能分析

• 批准号: 7721256
• 负责人: FRANK SICHERI
• 金额: $ 0.7万
• 依托单位: CORNELL UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-05-15 至 2009-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7721256
• 关键词: Binding Proteins; Cellular biology; Computer Retrieval of Information on Scientific Projects Database; Disease; Enzymes; F Box Domain; Family; Functional disorder; Funding; Goals; Grant; Human Genome; Hydroxyl Radical; Institution; Learning; Mutation; NDRG1 gene; Pharmaceutical Preparations; Phosphorylation; Phosphotransferases; Protein Kinase; Proteins; Research; Research Personnel; Resources; Side; Source; Stream; Structure; System; Therapeutic; United States National Institutes of Health; Viral; adapter protein; base; eIF-2 Kinase; human disease; inorganic phosphate; macromolecular assembly; novel; protein function; small molecule; stem; tumor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The human genome encodes just over 500 protein kinases. These enzymes regulate protein function by catalyzing the transfer of the gamma phosphate of ATP onto specific hydroxyl bearing side chains in target proteins. Protein phosphorylation influences protein function either by inducing conformational change or by promoting the formation of macromolecular assemblies. Aberrant protein kinase function arising from mutation or viral subversion mechanisms gives rise to cellular dysfunctions that underlie numerous human diseases. The ability to counteract aberrant protein kinase function through the use of small molecule therapeutics has validated the protein kinase as a drugable target. The pervasiveness of protein kinases as regulators of cellular biology, stems from a plasticity of structure that allows for the diversification of catalytic switching and substrate recognition mechanisms. To date only a small fraction of eukaryotic protein kinases have been structurally characterized. In my lab, we are seeking to uncover the structural basis for novel catalytic switching, substrate recognition and down-stream phospho-regulatory mechanisms. Our long-term goal is to make use of what we learn about protein kinases and phospho-regulatory systems to develop drugs to treat disease. Currently, my lab has x-ray crystallographic studies underway on 10 distinct protein kinase/phospho-regulatory systems. A partial list includes the RNA dependent protein kinase PKR, the polo family protein kinases, the NDR1 kinase regulator Mob1, the tumor suppresor F-box adapter protein Cdc4, and the phospho-inositide binding protein kinase Akt.

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 人类基因组编码了500多个蛋白激酶。这些酶通过催化三磷酸腺苷的伽马磷酸转移到靶蛋白中特定的含羟基侧链上来调节蛋白质的功能。蛋白质磷酸化通过诱导构象变化或促进大分子组装的形成来影响蛋白质的功能。突变或病毒颠覆机制引起的蛋白激酶功能异常会导致细胞功能障碍，这些疾病是许多人类疾病的基础。通过使用小分子疗法来对抗蛋白激酶功能异常的能力已经证实了蛋白激酶是一个可用药的靶点。 蛋白激酶作为细胞生物学调节剂的普遍性，源于一种结构的可塑性，这种结构允许催化开关和底物识别机制的多样化。到目前为止，只有一小部分真核蛋白激酶被结构表征。在我的实验室里，我们正在寻求揭示新型催化开关、底物识别和下游磷酸调节机制的结构基础。我们的长期目标是利用我们所学到的蛋白激酶和磷酸调节系统来开发治疗疾病的药物。目前，我的实验室正在对10个不同的蛋白激酶/磷酸调节系统进行X射线结晶学研究。部分清单包括RNA依赖的蛋白激酶PKR、POLO家族蛋白激酶、NDR1激酶调节因子Mob1、肿瘤抑制因子F-box适配蛋白CDC4和磷酸肌醇结合蛋白激酶Akt。